clinical trial · NCT07286370
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
GlaxoSmithKline·phase2·recruiting·n = 537
Salmonella InfectionsLow dose of iNTS-TCVFull dose of iNTS-TCVTYPHIBEVPrevenar 13NimenrixSaline
brief summary
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first dose administered at 6 months of age (MOA) or 6 weeks of age (WOA).
started
Apr 1, 2026
primary completion
Apr 27, 2028
completion
Apr 27, 2028
last updated
Apr 20, 2026
official title
A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol